RE:RE:Confirmation of X-ray activationHi bencro;
I like a good race, but not in this instance.
I agree with you completely that UHN/PMH will be on our side when results will be considered as a breakthrough. However, UHN/PMH and all of our collaborators present invoices to us that they expect to be paid promptly. We need their help now to promote ourselves and to raise the capital to pay those continuing costs. We are on the same team, right?
We are talking about slow to move Canada vs the USA with the FDA mandate to step it up a notch.
I really don't care for this stealth mode that we are enduring. Obviously, Roger nor UHN/PMH should reveal anything that would release information that is not well protected by patents. However, I am certain that the investors would prefer it If Roger would step it up a notch where possible.
The best luck to all longs;
made2last
bencro wrote: Freceach ... Great catch. Thanks for sharing.
It only confirms one thing; it's a race in the academic/scientific communities. So no doubt UHN/PMH
This one below comes from
The University of Chicago X-Ray Induced Photodynamic Therapy of Cancer :: ChemViews Magazine :: ChemistryViews First published: Published Date:
16 septembre 2017 However, using X-rays with greater depth penetration to activate a PS can extend the range and efficiency of the therapy to larger, deep-seated tumors. Wenbin Lin, University of Chicago, IL, USA, and colleagues have developed ultrathin nanoscale two-dimensional frameworks, known as metal–organic layers (MOLs), for use in X-ray induced PDT (X-PDT) of colon cancers. Heavy hafnium atom clusters within the MOLs absorb and then transfer X-ray energy to iridium or ruthenium bipyridine-containing PS linkers, where ROS are generated (pictured). The ROS diffuse easily through the ultrathin 2D MOLs (ca. 1.2 nm) into the surrounding tissue. The researchers injected MOLs into subcutaneous tumors grown on live mice, followed by a course of X-ray irradiation. X-PDT produced an up to 90 % reduction in tumor volumes, suggesting that the technology has great potential for reducing or eradicating aggressive tumors in living organisms. The ability of X-rays to penetrate deeply into tissue and efficient ROS diffusion through ultrathin 2D MOLs (ca. 1.2 nm) enable highly effective X-PDT to afford superb anticancer efficacy.